Analyzing tumor tissues and blood samples from glioblastoma patients
Analysis of Cell Count, Viability, and Immunogenicity of Deidentified Discarded Newly Diagnosed Glioblastoma Tissue and More Broadly Other Newly Diagnosed Solid Tumor Tissues From the Operating Room
Thomas Jefferson University · NCT04822688
This study is looking at tumor tissues and blood samples from glioblastoma patients to see how healthy the cells are and to learn more about how to create better treatments for brain cancer and other solid tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Thomas Jefferson University (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT04822688 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on collecting and analyzing discarded tumor tissues and blood samples from patients diagnosed with glioblastoma or other solid tumors. The primary objective is to assess the cell yield and viability of these samples upon arrival at the processing facility. Additionally, the study aims to explore the immunogenicity of the collected tissues, which may contribute to the development of future therapies for brain cancer and other solid tumors. By examining these biological samples, researchers hope to gain insights that could inform better treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with glioblastoma or other solid tumors and are undergoing surgical procedures.
Not a fit: Patients who are under 18 years old or those who are not surgical candidates may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved therapies for patients with glioblastoma and other solid tumors.
How similar studies have performed: Other studies have shown success in utilizing discarded tumor tissues for research, indicating that this approach is promising and not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provide signed and dated informed consent form * Any individual \>= 18 years old * Patients must have GBM or other solid tumor and undergoing surgery for diagnostic and therapeutic purposes Exclusion Criteria: * Individuals less than 18 years old * Unable to understand and give consent * Patients who are not surgical candidates
Where this trial is running
Philadelphia, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Study coordinator: Kevin Judy, MD
- Email: Kevin.Judy@jefferson.edu
- Phone: 215-955-7000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioblastoma, Malignant Solid Neoplasm